trial · primary record
AZD8421
ER+ HER2- Advanced Breast Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 55 |
| Primary completion | 2027-06-30 |
| Primary endpoint | Incidence of dose limiting toxicities (DLTs) as defined in the protocol. |
| Registry ID | NCT06188520 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:28.256Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06188520
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.